Showing results out of
Using machine learning to analyse the genetic factors behind early clinical trial termination, researchers find a link between genetic evidence and trial outcome.
SCIENCE & TECHNOLOGY2024
research-highlightsscience-technology
ARISE fellow Melanie Schneider shares how she uncovered a new interest in research infrastructures and supporting discovery.
PEOPLE & PERSPECTIVES2024
people-perspectivesperspectives
A new research paper published in Nature Communications lays the groundwork for the development of new drugs specific to genetic mutations or alterations responsible for the onset of tumours or genetic diseases.
SCIENCE & TECHNOLOGY2024
science-technology
EMBL Grenoble and the ESRF hosted a workshop bringing together representatives from research and industry to discuss the ever-growing role of artificial intelligence in the field of structural biology.
CONNECTIONS2024
connections
MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative’s collaborative efforts in drug discovery.
EMBL ANNOUNCEMENTS2024
announcementsembl-announcements
AI annotations added to the SureChEMBL database increase the depth of data made available to users.
2024
sciencetechnology-and-innovation
Enzymes constitute a large fraction of genomes – 20% in humans – which makes them a very important part of life. Despite decades of studies and a rich literature dedicated to understanding the reaction mechanisms of enzymes, the rules of enzyme catalysis are still not fully clear. A new…
SCIENCE & TECHNOLOGY2023
science-technologytechnology-and-innovation
David Hulcoop discusses how his experience bridging organisational cultures will help address critical challenges in drug discovery and target selection at Open Targets.
LAB MATTERSPEOPLE & PERSPECTIVES2023
announcementslab-matterspeople-perspectives
Coming from a pharmaceutical industry background, David Hulcoop is set to take over as Executive Director of the public-private partnership Open Targets.
EMBL ANNOUNCEMENTS2023
announcementsembl-announcements
A new tool for the interpretation of missense variation in humans – ProtVar – will help enable drug discovery.
SCIENCE & TECHNOLOGY2023
sciencescience-technologytechnology-and-innovation
EMBL-EBI is making a key contribution to a historic effort to understand the function of every human gene
LAB MATTERSSCIENCE & TECHNOLOGY2023
announcementslab-mattersscience-technology
Researchers create a network of interacting proteins – or interactome – to aid drug discovery.
2023
research-highlightsscience
EMBL is one of the partners of this project that aims to accelerate drug discovery and development, bringing in expertise from EMBL Grenoble and EMBL-EBI.
LAB MATTERSSCIENCE & TECHNOLOGY2023
lab-mattersscience-technology
Open Targets is using artificial intelligence and machine learning to identify and prioritise drug targets.
SCIENCE & TECHNOLOGY2023
sciencescience-technologytechnology-and-innovation
Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner.
CONNECTIONS2022
announcementsconnectionsscience
Ian Dunham walks us through his career so far including working on the human genome project, seeing his work on the cover of Nature and his current role as Director of Open Targets.
LAB MATTERSPEOPLE & PERSPECTIVES2021
lab-matterspeople-perspectives
EMBL will host a conference to look at the state of the pandemic, lessons learned, and ways to improve pandemic preparedness. Here’s a sneak peek into what promises to be another interesting and informative EMBL conference.
SCIENCE & TECHNOLOGY2021
eventsscience-technology
Researchers establish a framework for identifying new drugs capable of exploiting a cell’s own machinery.
SCIENCE & TECHNOLOGY2021
sciencescience-technology
EMBL Hamburg’s integrated structural biology facility has contributed to the success of a large-scale SARS-CoV-2 study
SCIENCE & TECHNOLOGY2021
sciencescience-technology
Researchers use large-scale human genetic studies to identify drug targets important for managing COVID-19 in its early stages
SCIENCE & TECHNOLOGY2021
sciencescience-technology
Scientists from the Beltrao Group at EMBL-EBI and collaborators identified drug targets common to SARS-CoV-2, SARS-CoV-1, and MERS-CoV, three pathogenic coronaviruses. They also found potential drugs that could be repurposed as COVID-19 treatments, and against emerging coronavirus strains in the…
SCIENCE & TECHNOLOGY2020
sciencescience-technology
The virtual EMBL Conference ‘SARS-CoV-2: Towards a New Era in Infection Research’ explored the importance of fundamental research, collaboration, and data science in containing the SARS-CoV-2 pandemic, and discussed opportunities to improve our response to pandemics in the future.
SCIENCE & TECHNOLOGY2020
eventsscience-technology
Open Targets welcomes new Informatics Science Director
LAB MATTERSPEOPLE & PERSPECTIVES2020
lab-matterspeople-perspectives
The infectious disease commonly known as flu is caused by the influenza virus. It spreads around the world in seasonal outbreaks, causing millions of infections and hundreds of thousands of deaths each year. Stephen Cusack, Head of EMBL Grenoble, has been studying different aspects of the influenza…
SCIENCE & TECHNOLOGY2020
sciencescience-technology
EMBL Hamburg and Tara raise awareness of the risks of microplastic pollution and global infection
EMBL ANNOUNCEMENTS2019
embl-announcementsevents
Large CRISPR screen prioritises hundreds of promising genes for personalised cancer treatment
SCIENCE & TECHNOLOGY2019
sciencescience-technology
New director drives drug discovery partnership forward
LAB MATTERSPEOPLE & PERSPECTIVES2019
lab-matterspeople-perspectives
Pharmaceutical company Sanofi strengthens drug targets discovery collaboration Open Targets
CONNECTIONSLAB MATTERS2018
connectionslab-matters
EMBL and Promega collaborate to train young scientists
CONNECTIONSLAB MATTERS2018
connectionslab-matters
New partner strengthens drug discovery collaboration
CONNECTIONSLAB MATTERS2018
connectionslab-matters
ERC grantee Stephen Cusack shares his vision for the next ten years
SCIENCE & TECHNOLOGY2017
sciencescience-technology
Takeda joins pioneering public-private drug discover collaboration Open Targets
LAB MATTERSPEOPLE & PERSPECTIVES2017
lab-matterspeople-perspectives
Alumnus Michael Parker talks about his career, research highlights and how EMBL has played a role
PEOPLE & PERSPECTIVES2017
alumnipeople-perspectives
Q&A with EMBL-EBI's Head of Chemical Biology data services
PEOPLE & PERSPECTIVES2017
people-perspectivesscience
ERC grantee Maja Köhn shares her vision for the next ten years
SCIENCE & TECHNOLOGY2017
sciencescience-technology
EMBL scientists add crucial knowledge to understanding of the bacterium that causes tuberculosis
SCIENCE & TECHNOLOGY2017
sciencescience-technology
Pioneering target validation collaboration expands to accelerate drug discovery research.
CONNECTIONSLAB MATTERS2016
connectionslab-matters
Mature cells can be reprogrammed to pluripotency and thus regain the ability to divide and differentiate into specialized cell types. Although these so-called induced pluripotent stem cells (iPS cells) represent a milestone in stem cell research, many of the biochemical processes that underlie…
SCIENCE & TECHNOLOGY2013
sciencescience-technology
ChEMBLdb, a vast online database of information on the properties and activities of drugs and drug-like small molecules and their targets, launches today with information on over half a million compounds. The data lie at the heart of translating information from the human genome into successful new…
SCIENCE & TECHNOLOGY2010
sciencescience-technology
The Wellcome Trust has awarded £4.7 million (€5.8 million) to EMBL’s European Bioinformatics Institute (EMBL-EBI) to support the transfer of a large collection of information on the properties and activities of drugs and a large set of drug-like small molecules from the publicly listed…
LAB MATTERS2008
lab-matters
Today EMBL scientists, EMBL’s commercial affiliate, EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) and EMBL’s venture vehicle, EMBL Ventures GmbH, announce the foundation of Elara Pharmaceuticals GmbH, a start-up company that will translate basic research findings into new…
LAB MATTERSSCIENCE & TECHNOLOGY2006
lab-mattersscience-technology
Tuberculosis remains one of the deadliest threats to public health. Every year two million people die of the disease, which is caused by the microorganism Mycobacterium tuberculosis. Roughly one third of the world’s population is infected and more and more bacterial strains have developed…
SCIENCE & TECHNOLOGY2006
sciencescience-technology
A detailed structural picture of a molecule that plays a key role in activating the Epstein Barr Virus in human cells has now been obtained by researchers at the European Molecular Biology Laboratory (EMBL) and the Institut de Virologie Moléculaire et Structurale (IVMS), associated with the…
SCIENCE & TECHNOLOGY2006
sciencescience-technology
No results found